AU2019359807B2 - Avexitide for the treatment of hyperinsulinemic hypoglycemia - Google Patents

Avexitide for the treatment of hyperinsulinemic hypoglycemia Download PDF

Info

Publication number
AU2019359807B2
AU2019359807B2 AU2019359807A AU2019359807A AU2019359807B2 AU 2019359807 B2 AU2019359807 B2 AU 2019359807B2 AU 2019359807 A AU2019359807 A AU 2019359807A AU 2019359807 A AU2019359807 A AU 2019359807A AU 2019359807 B2 AU2019359807 B2 AU 2019359807B2
Authority
AU
Australia
Prior art keywords
avexitide
hypoglycemia
administered
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019359807A
Other languages
English (en)
Other versions
AU2019359807A1 (en
Inventor
Colleen M. CRAIG
Lisa Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylyx Pharmaceuticals Inc
Original Assignee
Amylyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylyx Pharmaceuticals Inc filed Critical Amylyx Pharmaceuticals Inc
Publication of AU2019359807A1 publication Critical patent/AU2019359807A1/en
Assigned to AMYLYX PHARMACEUTICALS, INC. reassignment AMYLYX PHARMACEUTICALS, INC. Request for Assignment Assignors: EIGER BIOPHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2019359807B2 publication Critical patent/AU2019359807B2/en
Priority to AU2025208421A priority Critical patent/AU2025208421A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019359807A 2018-10-15 2019-10-15 Avexitide for the treatment of hyperinsulinemic hypoglycemia Active AU2019359807B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025208421A AU2025208421A1 (en) 2018-10-15 2025-07-23 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862745915P 2018-10-15 2018-10-15
US62/745,915 2018-10-15
US201862746229P 2018-10-16 2018-10-16
US62/746,229 2018-10-16
US201962823493P 2019-03-25 2019-03-25
US62/823,493 2019-03-25
PCT/US2019/056278 WO2020081534A1 (en) 2018-10-15 2019-10-15 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025208421A Division AU2025208421A1 (en) 2018-10-15 2025-07-23 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Publications (2)

Publication Number Publication Date
AU2019359807A1 AU2019359807A1 (en) 2021-05-13
AU2019359807B2 true AU2019359807B2 (en) 2025-04-24

Family

ID=70283142

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019359807A Active AU2019359807B2 (en) 2018-10-15 2019-10-15 Avexitide for the treatment of hyperinsulinemic hypoglycemia
AU2025208421A Pending AU2025208421A1 (en) 2018-10-15 2025-07-23 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025208421A Pending AU2025208421A1 (en) 2018-10-15 2025-07-23 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Country Status (10)

Country Link
US (1) US20210338780A1 (enExample)
EP (2) EP3867266A4 (enExample)
JP (2) JP2022513351A (enExample)
CN (1) CN112867730A (enExample)
AU (2) AU2019359807B2 (enExample)
BR (1) BR112021006968A2 (enExample)
CA (1) CA3115527A1 (enExample)
CL (1) CL2021000892A1 (enExample)
IL (2) IL314504A (enExample)
WO (1) WO2020081534A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
US20240307501A1 (en) 2021-06-21 2024-09-19 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
WO2024220962A1 (en) * 2023-04-21 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Glp-1r antagonism to improve nutrition following gastrointestinal surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191395A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
WO2018094404A1 (en) * 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) * 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US10653753B2 (en) * 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191395A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
WO2018094404A1 (en) * 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Also Published As

Publication number Publication date
AU2019359807A1 (en) 2021-05-13
EP4233842A2 (en) 2023-08-30
WO2020081534A1 (en) 2020-04-23
IL314504A (en) 2024-09-01
AU2025208421A1 (en) 2025-08-14
CN112867730A (zh) 2021-05-28
US20210338780A1 (en) 2021-11-04
CA3115527A1 (en) 2020-04-23
EP4233842A3 (en) 2023-10-25
EP3867266A1 (en) 2021-08-25
JP2025000798A (ja) 2025-01-07
IL282059A (en) 2021-05-31
BR112021006968A2 (pt) 2021-07-27
JP2022513351A (ja) 2022-02-07
CL2021000892A1 (es) 2021-11-12
EP3867266A4 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
US20250255935A1 (en) Treatment of post-bariatric hypoglycemia with glp-1 antagonist exendin(9-39)
AU2025208421A1 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia
JP2019535734A5 (enExample)
HK40014636B (en) Buffered formulations of exendin (9-39)
HK40014636A (en) Buffered formulations of exendin (9-39)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AMYLYX PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): EIGER BIOPHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)